Credits: Canva
Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.
The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.
The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.
ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are
Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.
Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.
The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.
RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.
However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.
Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.
For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.
Credit: iStock
According to the American Academy of Dermatology, skin cancer causes about 60,000 deaths every year globally. The current estimates also show that about one in five Americans is at risk of having the deadly disease in their lifetime. Though the technology of curing skin cancer is very advanced, the early detection of the disease is still a very crucial aspect in the path to getting a full cure.
And now, the researchers have come up with the smart tattoo technology, which can be a game-changer in this aspect.
A recent research study led by Professor Jinyang Liang from the Institut national de la recherche scientifique (INRS), an expert in ultrafast imaging and biophotonics, has shed light on promising smart tattoo technology that can aid in detecting skin cancer. The study was conducted in collaboration between the INRS in Québec and Université de Montréal.
The process that Professor Liang and his team have researched is Single-shot Microneedle-Encoded Upconversion Lifetime Mapping (SMEAR-ULM), which is a great leap forward in skin cancer detection.SMEAR-ULM monitors microscopic temperature changes on the skin surface that signal the pernicious transformations with unprecedented sensitivity.
Skin cancer is, without a doubt, one of the most deadly ailments known to man, and among its three types, melanoma is the most notorious one. Early detection in case of melanoma is very important for its cure. The current state of the treatment process depends heavily on visual examinations and invasive biopsies, which are known to cause discomfort for patients as well as occasional unnecessary interventions due to false positives, and SMEAR-ULM is a possible answer to these problems.
Read Also: Melanoma Is Being Overdiagnosed. Here's Everything You Should Know
Melanoma is a type of skin cancer that develops in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its colour. It can occur anywhere on the skin but often develops on areas exposed to the sun, such as the face, arms, back, and legs. Melanoma can also appear in less-exposed areas, like the soles of the feet, palms, or under the nails, particularly in individuals with darker skin tones. Although rare, melanoma may develop in the eyes, mouth, or internal organs.
The primary sign of melanoma is a new or changing mole, freckle, or skin lesion. The "ABCDE rule" helps identify suspicious moles:
Additional symptoms may include itching, bleeding, or a sore that doesn’t heal. Prompt medical attention is essential for suspicious skin changes.
Credit: iStock
The suspected case of Ebola infection in a young woman in Bengaluru who had returned from Ebola-affected Uganda has tested negative, India's Ministry of Health & Family Welfare has confirmed.
The woman who arrived in Bengaluru from Kampala, Uganda, on May 23, was suspected of infection after developing mild symptoms, including body aches. She was shifted from a hotel to the state-run Epidemic Diseases Hospital on May 26, and her samples were sent to the National Institute of Virology in Pune.
"The test result has returned negative for Ebola Virus Disease," the Ministry said, adding that there is "no confirmed case of Ebola in India".
The Ministry said that although the woman remained healthy apart from a mild body ache, she was isolated and tested as part of the precaution measures instated in the country against the Ebola outbreak, which has so far affected over 900 people and led to more than 200 deaths in the Democratic Republic of Congo and Uganda. As per African health officials, 10 nations on the continent are at high risk.
Also read: Russia's New Ebola Vaccine To Protect Against Rare Bundibugyo Strain, Says Health Minister
Dr. Rajeev Jayadevan, Co-Chairman of the National IMA COVID Task Force and Past President of the Indian Medical Association, Cochin, told HealthandMe, that the spread of the outbreak to other countries may not be surprising.
“With air travel being common and the outbreak already having spread to multiple countries in Africa, it is entirely possible for someone who had contact with a person with Ebola virus disease to get on a flight to another country,” Dr. Rajeev said.
“All patients with Ebola disease may not know they have it — as the initial symptoms are nonspecific, such as fever and body ache. In addition, scarcity of the exact PCR test to diagnose the latest Bundibugyo Ebola virus in Africa makes it possible to miss it entirely,” he added.
World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus earlier stated he was “deeply concerned about the scale and speed of the epidemic”.
He added that the ongoing outbreak "is spreading rapidly" and "outpacing us".
The global health agency has also determined that the deadly outbreak is a “Public Health Emergency of International Concern (PHEIC)”.
Read More: Why Ebola Outbreaks Keep Returning In Africa? | Explained
In view of the outbreak, the Ministry of Health, in coordination with the concerned State authorities, is maintaining close surveillance, and all necessary public health protocols are being followed in accordance with WHO guidelines.
The government said it "remains vigilant and prepared, with screening and surveillance measures continuing at all designated Points of Entry and across the public health system".
Citizens are advised not to panic, avoid spreading misinformation, and rely only on official sources for information.
The government also issued guidelines for passengers arriving from Ebola-affected countries. As part of the precautionary measures, travelers entering the country from such nations are required to undergo a 21-day quarantine period.
Ebola disease is a severe viral hemorrhagic fever with a high mortality rate.
Ebola spreads through:
• Direct contact with infected blood or bodily fluids
• Contact with contaminated surfaces or medical equipment
• Unsafe caregiving exposure
• Traditional burial practices involving direct contact
• Certain zoonotic animal exposures.
Symptoms to watch for include:
• fever,
• weakness,
• headache,
• muscle pain,
• vomiting,
• diarrhea,
• sore throat,
• unexplained bleeding.
Credit: iStock
Russia today claimed that its scientists have developed a novel vaccine against a new Ebola strain.
According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".
It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.
The vaccine, for which "clinical trials would take place, as per Anne Ancia, the WHO’s representative in the DRC, comes as a hope against the Bundibugyo strain, with no vaccine or antiviral available.
The strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.
Earlier this week, Russia’s consumer health watchdog Rospotrebnadzor announced it would send specialists to Africa to help fight the Ebola outbreak, GxP News reported.
The country noted that it will also supply Russian-developed diagnostic tests.
Health Minister Murashko said he and WHO Director-General Tedros Adhanom Ghebreyesus had discussed the supply of Russian vaccines to the DRC and Uganda in the context of the Ebola outbreak.
“Specialists are already deploying to provide assistance. We discussed this with Dr Tedros, the head of the World Health Organisation,” Murashko said.
Gintsburg believes that "medical workers in outbreak zones should be vaccinated with the existing vaccine, even though no targeted efficacy tests against this strain have been conducted".
He also stressed the need to develop a separate vaccine against Bundibugyo. However, the institute does not yet have a sample of this pathogen.
“I believe the existing vaccine may confer immunity against this pathogen, though we have not tested it. In the absence of other means, it should be used,” he told Izvestia, a Russian Newspaper.
Scientists at Oxford University are also developing a new vaccine that could be ready for clinical trials within two to three months to help tackle the Ebola emergency.
The vaccine uses the same technology the team developed during the COVID pandemic. It is a highly adjustable technology - known as ChAdOx1 - that can be quickly tweaked so it works against different infections.
Another separate experimental Bundibugyo vaccine is also in development, but it is expected to take six to nine months for any dose of that to be ready for testing, BBC reported.
The WHO has also recommended prioritizing two monoclonal antibodies for clinical trials.
"We are also recommending the evaluation of the antiviral obeldesivir in a clinical trial as post-exposure prophylaxis for people who are high-risk contacts," the WHO chief said.
This clinical trial is now being developed jointly with Africa CDC and the Collaborative Open Research Consortium on filoviruses, he noted.
Ebola disease is a severe viral hemorrhagic fever with a high mortality rate.
Ebola spreads through:
• Direct contact with infected blood or bodily fluids
• Contact with contaminated surfaces or medical equipment
• Unsafe caregiving exposure
• Traditional burial practices involving direct contact
• Certain zoonotic animal exposures.
Symptoms to watch for includes:
• fever,
• weakness,
• headache,
• muscle pain,
• vomiting,
• diarrhea,
• sore throat,
• unexplained bleeding.
© 2024 Bennett, Coleman & Company Limited